Back to companies

Relmada Therapeutics Inc: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Relmada Therapeutics Inc (Relmada Therapeutics) is a clinical-stage biotechnology company. It focuses on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. The company’s pipeline product

Gain a 360-degree view of Relmada Therapeutics Inc and make more informed decisions for your business Gain a 360-degree view of Relmada Therapeutics Inc and make more informed decisions for your business Register your interest
Headquarters United States of America

Address 3rd Floor, 2222 Ponce De Leon Boulevard, Coral Gables, Florida, 33134


Telephone 1 786 6291376

No of Employees 17

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange RLMD (NASD)

EPS XYZ

Net Income (2024) XYZ 28.3% (2024 vs 2023)

Market Cap* $434.2M

Net Profit Margin (0 vs) XYZ 0.0% (2024 vs 2023)

   

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Register your interest

Products and Services

Products
Pipeline
NDV-01: Non-Muscle Invasive Bladder Cancer
Sepranolone: Prader-Willi Syndrome (PWS)
Understand Relmada Therapeutics Inc portfolio and identify potential areas for collaboration Understand Relmada Therapeutics Inc portfolio and identify potential areas for collaboration Register your interest

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2025 Asset Purchase In February, the company acquired Sepranolone for the treatment of Tourette syndrome and other compulsion-related conditions from Asarina Pharma AB.
2021 Acquisitions/Mergers/Takeovers In July, the company announced the acquisition of development and commercial rights to a novel psilocybin and derivate program from Arbormentis LLC.
2018 Acquisitions/Mergers/Takeovers In January, Relmada Therapeutics acquired the global rights to develop and market dextromethadone (REL-1017), a novel N-methyl-D-aspartate receptor antagonist to treat disorders of the nervous system.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Register your interest
Image for loader

Competitor Comparison

Key Parameters Relmada Therapeutics Inc Alpine Immune Sciences Inc Cidara Therapeutics Inc EOM Pharmaceuticals Holdings Inc Juno Therapeutics Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Coral Gables Seattle San Diego Westlake Village Seattle
State/Province Florida Washington California California Washington
No. of Employees 17 142 38 3 533
Entity Type Public Private Private Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Register your interest
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Register your interest
Executives
Name Position Board Since Age
Charles J. Casamento Chairman Executive Board 2017 77
Sergio Traversa Chief Executive Officer; Director Executive Board 2012 63
Paul Kelly Chief Operating Officer; Director Executive Board 2015 65
Maged Shenouda Chief Financial Officer Senior Management 2020 59
Charles Ence Chief Accounting Officer; Chief Compliance Officer Senior Management 2020 64
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Relmada Therapeutics Inc key executives to enhance your sales strategy Gain insight into Relmada Therapeutics Inc key executives to enhance your sales strategy Register your interest
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?